Compare EXPI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXPI | DBVT |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2010 | 2014 |
| Metric | EXPI | DBVT |
|---|---|---|
| Price | $5.98 | $20.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $9.75 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 1.0M | 252.2K |
| Earning Date | 05-05-2026 | 03-26-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,147,681.00 | $5,636,000.00 |
| Revenue This Year | $6.93 | $79.21 |
| Revenue Next Year | $5.37 | $1,754.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 220.39 | 35.77 |
| 52 Week Low | $5.66 | $6.00 |
| 52 Week High | $12.23 | $26.19 |
| Indicator | EXPI | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 35.34 | 51.33 |
| Support Level | $5.66 | $20.23 |
| Resistance Level | $6.31 | $24.16 |
| Average True Range (ATR) | 0.29 | 1.12 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 49.26 | 73.10 |
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.